BioNTech SE Sponsored ADR $BNTX Holdings Decreased by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft lowered its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 136,425 shares of the company’s stock after selling 15,914 shares during the quarter. BioNTech comprises about 0.9% of Baader Bank Aktiengesellschaft’s portfolio, making the stock its 21st biggest holding. Baader Bank Aktiengesellschaft’s holdings in BioNTech were worth $11,997,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares during the period. GSK plc bought a new stake in shares of BioNTech during the 4th quarter worth about $84,711,000. Morgan Stanley lifted its stake in shares of BioNTech by 12.9% in the 4th quarter. Morgan Stanley now owns 680,669 shares of the company’s stock worth $64,800,000 after acquiring an additional 77,653 shares during the period. Bank of America Corp DE lifted its stake in shares of BioNTech by 344.4% in the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after acquiring an additional 444,332 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of BioNTech by 2.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock valued at $52,416,000 after acquiring an additional 13,788 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of a number of research analyst reports. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Wells Fargo & Company cut their target price on BioNTech from $150.00 to $140.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $130.00 price target on shares of BioNTech in a research note on Monday, April 27th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $129.12.

BioNTech Stock Performance

Shares of BNTX opened at $92.16 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74. The firm’s 50 day moving average is $91.32 and its 200-day moving average is $97.81. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market capitalization of $23.31 billion, a P/E ratio of -15.67 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, May 4th. The company reported ($2.26) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.26. The business had revenue of $136.71 million during the quarter, compared to analyst estimates of $207.42 million. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business’s quarterly revenue was down 35.4% on a year-over-year basis. During the same period in the prior year, the business earned ($1.73) earnings per share. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -5.79 EPS for the current fiscal year.

BioNTech declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the transaction, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.